Tvardi Therapeutics (TVRD) Share-based Compensation (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Share-based Compensation of $370000.0 for Q1 2026, up 4.82% sequentially from $353000.0 in Q4 2025, and up 362.5% YoY from $80000.0 in Q1 2025.
Tvardi Therapeutics (TVRD) Share-based Compensation (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Share-based Compensation for 14 years, with the latest figure at $370000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 362.5% year-over-year to $370000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 349.69% YoY) and the FY2025 annual result came in at $3.8 million, down 8.35% from the prior year.
- Share-based Compensation advanced to $370000.0 in Q1 2026 per TVRD's latest filing, from $353000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $5.7 million in Q1 2022 and troughed at $79000.0 in Q2 2024.
- A 5-year average of $1.3 million and a median of $353000.0 in 2025 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation tumbled 97.81% in 2024, then jumped 4525.0% in 2025.
- Over 5 years, Share-based Compensation stood at $3.8 million in 2022, then declined by 5.26% to $3.6 million in 2023, then sank by 97.81% to $79000.0 in 2024, then surged by 346.84% to $353000.0 in 2025, then climbed by 4.82% to $370000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $370000.0, $353000.0, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | 3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 370,000.00 |
| Mar 31, 2026 | 370,000.00 |
| Dec 31, 2025 | 353,000.00 |
| Dec 31, 2025 | 353,000.00 |
| Sep 30, 2025 | 3.70 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 627,000.00 |
| Jun 30, 2025 | 627,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Dec 31, 2024 | 79,000.00 |
| Dec 31, 2024 | 79,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 79,000.00 |
| Jun 30, 2024 | 79,000.00 |
| Mar 31, 2024 | 81,000.00 |
| Mar 31, 2024 | 81,000.00 |
| Dec 31, 2023 | 3.60 Mn |
| Dec 31, 2023 | 3.60 Mn |